A new Sejaro preparation has been registered in the Republic of Uzbekistan for the treatment of obesity and Type 2 diabetes. This medication contains the substance tirzepatide, which activates two incretin hormone receptors in the body. As a result, the feeling of hunger decreases and the craving for high-calorie foods is alleviated. This process helps prevent weight gain and also ensures a reduction in visceral fat tissue volume and waist circumference. The significance of this innovative medication is expected to open new opportunities in the healthcare sector in the country.
SourceKun.uz